Novo Nordisk India today announced price reductions for its original and well-established semaglutide injections for patients living with type 2 diabetes and obesity or overweight. Effective April 1, 2026, the price of the starting dose of Ozempic®will be reduced by 36%, while that of the starting dose of Wegovy® will be reduced by 48% in India. Ozempic® (0.25 mg) and Wegovy® (0.25 mg) will now be available in India at an effective daily price of Rs. 202 or a weekly price of Rs. 1,415 inclusive of taxes.This is done to make theseinnovative therapies,that are supported by robust clinical evidence and high scientific standards, more accessible to a larger section of people living with diabetes and obesity in India.
Commenting on this move, Vikrant Shrotriya, Managing Director, Novo Nordisk India said,“We’re driven by science, but our focus is always on patients. By revising the price of our innovative treatments, we’re trying to make best-in-class cardiometabolic care more affordable for as many people with type 2 diabetes, overweightandobesityin India as possible. We’ve heard from patients and doctors, and we’re acting on that feedback. The burden of diabetes, obesity and related complications is immense for India, and we aim to bend this curve with effective, safe, and time-tested solutions.”
Ozempic® is the only GLP-1 RA with the broadest range of benefits for people with type 2 diabetes (PwT2D), proven to provide significant glycaemic control, compelling weight loss, along with risk reduction of cardiovascular and kidney events in PwT2D.2 Wegovy® delivers quality and sustainable weight loss with proven cardiovascular benefits in people living with overweight/obesity.2Both are indicated adjunct to diet and exercise and are prescription only medications that should be used in line with their approved indication under the supervision of a healthcare professional.2,3
Novo Nordisk’s semaglutide, the active pharmaceutical ingredient in Wegovy® and Ozempic®, is backed by 50+ clinical trials, 49 million patient years of exposure, and extensive real-world evidence1. Both therapies are manufactured using rDNA technology, are available in apen device with established safety standards,andfollow a robust nation-wide cold chain management process. For patients, this translates into a treatment option with a well-established safety and efficacy profile. Injectable semaglutideis approved by regulatory authoritiesacross 75 countries including the Drugs Controller General of India (DCGI), European Medicines Agency (EMA), United States Food & Drug Administration (US FDA) and Pharmaceuticals and Medical Devices Agency (PMDA), Japan2-9.